Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
The article compares Novo Nordisk and Pfizer as investment choices for 2027. Novo Nordisk dominates the high-growth obesity and diabetes treatment markets with blockbuster drugs like Wegovy and Ozempic, but faces pricing pressures and competition from rivals like Eli Lilly. Pfizer offers a diversified portfolio, stronger cash position ($14.3B vs $6.8B), and cheaper valuation, making it the better turnaround bet despite slower growth. Both companies face headwinds from pricing pressures and competitive threats.


